[go: up one dir, main page]

MX2020003198A - Bacterias acidolácticas novedosas y uso de las mismas. - Google Patents

Bacterias acidolácticas novedosas y uso de las mismas.

Info

Publication number
MX2020003198A
MX2020003198A MX2020003198A MX2020003198A MX2020003198A MX 2020003198 A MX2020003198 A MX 2020003198A MX 2020003198 A MX2020003198 A MX 2020003198A MX 2020003198 A MX2020003198 A MX 2020003198A MX 2020003198 A MX2020003198 A MX 2020003198A
Authority
MX
Mexico
Prior art keywords
lactic acid
novel lactic
acid bacteria
mental illness
diagnosing
Prior art date
Application number
MX2020003198A
Other languages
English (en)
Inventor
Dong Hyun Kim
Myung Joo Han
Original Assignee
Univ Industry Cooperation Group Kyung Hee Univ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Industry Cooperation Group Kyung Hee Univ filed Critical Univ Industry Cooperation Group Kyung Hee Univ
Publication of MX2020003198A publication Critical patent/MX2020003198A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • C12Q1/10—Enterobacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/225—Lactobacillus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/304—Mood disorders, e.g. bipolar, depression
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)

Abstract

La presente invención se refiere a una bacteria acidoláctica novedosa y, más en particular, a una composición que comprende Lactobacillus reuteri NK33 (KCCM12090P) o Bifidobacterium adolescentis NK98 (KCCM12297P), que es la bacteria acidoláctica novedosa, útil en la prevención y el tratamiento de una enfermedad mental neurológica o una enfermedad inflamatoria. Además, la presente invención se refiere a una composición para diagnosticar una enfermedad mental neurológica, que comprende una preparación para medir el nivel de un microorganismo intestinal, un kit que la comprende y un método para diagnosticar la enfermedad mental neurológica, que comprende una etapa de medición del nivel del microorganismo intestinal.
MX2020003198A 2017-09-29 2018-09-28 Bacterias acidolácticas novedosas y uso de las mismas. MX2020003198A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170127422 2017-09-29
PCT/KR2018/011607 WO2019066599A2 (ko) 2017-09-29 2018-09-28 신규 유산균 및 이의 용도

Publications (1)

Publication Number Publication Date
MX2020003198A true MX2020003198A (es) 2020-10-12

Family

ID=65902558

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020003198A MX2020003198A (es) 2017-09-29 2018-09-28 Bacterias acidolácticas novedosas y uso de las mismas.
MX2024011127A MX2024011127A (es) 2017-09-29 2020-03-20 Bacterias acidolacticas novedosas y uso de las mismas.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2024011127A MX2024011127A (es) 2017-09-29 2020-03-20 Bacterias acidolacticas novedosas y uso de las mismas.

Country Status (11)

Country Link
US (1) US12447184B1 (es)
EP (1) EP3715448A4 (es)
JP (2) JP7038202B2 (es)
KR (3) KR102260489B1 (es)
CN (2) CN116286509A (es)
AU (2) AU2018341753B2 (es)
BR (1) BR112020005747A2 (es)
CA (2) CA3199327A1 (es)
MX (2) MX2020003198A (es)
SG (2) SG11201911984QA (es)
WO (1) WO2019066599A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102049700B1 (ko) 2019-07-31 2019-11-28 (주) 에이투젠 락토바실러스 루테리 atg-f4를 포함하는 근육질환 예방 또는 치료용 조성물
KR102819613B1 (ko) 2020-01-23 2025-06-12 엠앤에이치바이오 주식회사 락토바실러스 루테리 ubc-u80, 및 이의 퇴행성 뇌질환 예방 및 치료 용도
KR102136522B1 (ko) * 2020-03-04 2020-07-22 주식회사 락토메이슨 안전성 및 장부착능이 우수한 모유유래 락토바실러스 루테리 lm1071 균주, 및 상기 균주 또는 이의 배양물을 포함하는 조성물
EP3932415A1 (en) 2020-07-01 2022-01-05 Fundació Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta (IDIBGI) Gut microbiota composition and uses thereof
CN112029844B (zh) * 2020-07-30 2021-10-19 中国医学科学院病原生物学研究所 肠道微生物在诊断肌张力障碍症中的应用
KR102875769B1 (ko) 2020-08-20 2025-10-24 주식회사 리스큐어바이오사이언시스 락토바실러스 사케이 또는 이로부터 유래된 세포밖 소포체를 유효성분으로 포함하는 뇌질환의 치료용 조성물
KR102215599B1 (ko) * 2020-12-28 2021-02-15 주식회사 에이치이엠 신규한 비피도박테리움 애니멀리스 락티스 hem20-01 균주, 및 상기 균주 또는 이의 배양물을 포함하는 우울증 치료용 조성물
CN114790475B (zh) * 2021-01-25 2025-01-10 首都医科大学附属北京天坛医院 一种与亨廷顿病相关的肠道微生物及其应用
CN113122473B (zh) * 2021-04-10 2022-08-02 江南大学 增强记忆能力的乳酸杆菌bb1及其应用
CN114098084A (zh) * 2021-04-13 2022-03-01 中国人民解放军军事科学院军事医学研究院 一种缓解长期低剂量辐射暴露所致认知损伤的益生菌组合物及其应用
CN113073066B (zh) * 2021-04-16 2022-01-04 段云峰 罗伊氏乳杆菌及其应用、组合物、药物和食品
CN113180109B (zh) * 2021-04-16 2022-02-18 段云峰 罗伊氏乳杆菌在制备预防或治疗发育障碍类疾病产品中的应用
KR102792000B1 (ko) * 2021-10-21 2025-04-08 경북대학교 산학협력단 신규한 락토바실러스 루테리 psc102 균주 및 이의 용도
KR20230108616A (ko) 2022-01-11 2023-07-18 주식회사 엘지에너지솔루션 이차전지 집전체의 활물질 코팅을 위한 다이 코터
KR102645749B1 (ko) * 2023-04-24 2024-03-13 주식회사 메디오젠 면역 증진 및 장 건강 증진 활성을 가진 락토바실러스 루테리 mg5462 균주 및 이를 포함하는 조성물
WO2025058081A1 (ja) * 2023-09-14 2025-03-20 江崎グリコ株式会社 総合注意力、認知柔軟性及び／又は実行機能を改善するための組成物
WO2025206186A1 (ja) * 2024-03-27 2025-10-02 雪印メグミルク株式会社 ストレス低減用組成物、飲食品、医薬品及び飼料

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008195635A (ja) * 2007-02-09 2008-08-28 Crossfield Bio Inc 馬用乳酸菌製剤
PL2419114T5 (pl) * 2009-05-01 2019-09-30 Uas Laboratories Llc Kompozycje bakteryjne do profilaktyki i leczenia choroby degeneracyjnej
WO2011148219A1 (en) 2010-05-28 2011-12-01 Compagnie Gervais Danone Probiotic strains for use in improving the enteric nervous system
EP2609814A1 (en) * 2011-12-30 2013-07-03 Nestec S.A. Lactobacillus reuteri DSM 17938 for the development of cognitive function
FI127671B (en) * 2014-05-28 2018-11-30 Filip Scheperjans Method for diagnostics of Parkinson’s disease
US10022408B2 (en) * 2014-08-29 2018-07-17 Chr. Hansen A/S Probiotic Bifidobacterium adolescentis strains
WO2016168359A1 (en) 2015-04-13 2016-10-20 uBiome, Inc. Method and system for microbiome-derived diaganostics and therapeutics for mental health associated conditions
WO2016167365A1 (ja) 2015-04-16 2016-10-20 国立研究開発法人国立精神・神経医療研究センター 精神疾患バイオマーカー
KR20170032815A (ko) 2015-09-15 2017-03-23 경희대학교 산학협력단 신규 유산균 및 퇴행성 뇌질환 또는 인지기능의 예방, 개선 또는 치료용 조성물
RU2616899C1 (ru) 2015-10-19 2017-04-18 Федеральное государственное бюджетное учреждение науки Институт общей генетики им. Н.И. Вавилова Российской академии наук (ИОГЕН РАН) Противовоспалительная фармацевтическая композиция на основе бактериальных штаммов
KR101935019B1 (ko) 2015-11-26 2019-01-03 몰렉스 엘엘씨 확산 렌즈 및 이를 포함하는 발광 모듈
KR101937364B1 (ko) * 2016-01-28 2019-01-11 경희대학교 산학협력단 면역조절 작용을 가는 사람 소화관 유래 신규 유산균 및 이의 용도
JP7216998B2 (ja) 2016-03-14 2023-02-02 ホロバイオーム， インコーポレイテッド 中枢神経系の精神障害または疾患を処置するための腸ミクロビオームの改変
CN107699517A (zh) * 2017-10-17 2018-02-16 无限极（中国）有限公司 一种青春双歧杆菌及其用途
CN108261425A (zh) * 2017-12-31 2018-07-10 温州医科大学附属第二医院、温州医科大学附属育英儿童医院 一种减轻阿尔茨海默病的功能性低聚糖组合物及其制备方法与应用

Also Published As

Publication number Publication date
KR102260489B1 (ko) 2021-06-04
RU2020114781A (ru) 2021-10-29
NZ762407A (en) 2023-09-29
EP3715448A2 (en) 2020-09-30
WO2019066599A2 (ko) 2019-04-04
US12447184B1 (en) 2025-10-21
EP3715448A4 (en) 2021-06-30
JP2022071102A (ja) 2022-05-13
WO2019066599A3 (ko) 2019-05-23
JP7038202B2 (ja) 2022-03-17
KR20220004233A (ko) 2022-01-11
AU2018341753A1 (en) 2020-03-26
SG10201913043TA (en) 2020-03-30
AU2018341753B2 (en) 2021-11-18
AU2021282468A1 (en) 2022-01-06
MX2024011127A (es) 2024-09-18
CA3063669A1 (en) 2019-12-06
CN116286509A (zh) 2023-06-23
CA3199327A1 (en) 2019-04-04
CN111465684A (zh) 2020-07-28
CN111465684B (zh) 2023-03-31
RU2020114781A3 (es) 2021-10-29
KR20210064173A (ko) 2021-06-02
SG11201911984QA (en) 2020-01-30
KR102655293B1 (ko) 2024-04-05
BR112020005747A2 (pt) 2020-10-13
AU2021282468B2 (en) 2023-10-05
JP2020534853A (ja) 2020-12-03
CA3063669C (en) 2023-08-01
JP7307216B2 (ja) 2023-07-11
KR102348851B1 (ko) 2022-01-12
KR20190038451A (ko) 2019-04-08

Similar Documents

Publication Publication Date Title
MX2020003198A (es) Bacterias acidolácticas novedosas y uso de las mismas.
EP4364745A3 (en) Novel lactic acid bacteria and use thereof
Haghshenas et al. Different effects of two newly-isolated probiotic Lactobacillus plantarum 15HN and Lactococcus lactis subsp. Lactis 44Lac strains from traditional dairy products on cancer cell lines
CO2018010954A2 (es) Nuevo uso médico de probioticos
BR112022000280A2 (pt) Cepa bacteriana de bifidobacterium bifidum, suas composições e usos relacionados
Hamidi et al. The aflatoxin B1 isolating potential of two lactic acid bacteria
MX2022003372A (es) Cepas bacterianas, sus composiciones y su uso para el tratamiento de trastornos gastrointestinales.
CL2018001133A1 (es) Faecalibacterium prausnitzii y desulfovibrio piger para uso en el tratamiento o prevención de la diabetes y enfermedades intestinales
PE20210322A1 (es) Composiciones que comprenden microbiota coseleccionada y metodos para su uso
BR112012016982B8 (pt) bactéria de ácido lático recombinante de grau alimentício e composição terapêutica
EA201991301A1 (ru) Урогенитальная композиция для медицинского устройства на основе подходящих биохимических композиций для стабилизации кислотности и редокс-состояния вагинальной жидкости
BR112012033212A2 (pt) uso de lactobacillo inibindo a produção de gás de bactéria coliforme isolada em infantes afetados por cólica
MX2017016283A (es) Lactobacillus paracasei para la produccion de acido linoleico conjugado, preparaciones nutricionales y farmaceuticas que lo contienen y sus usos.
BR112016026654A2 (pt) Composições contendo ácido bórico e uma mistura de lactobacillus
BR112019001984A2 (pt) bactérias lácticas e a sua utilização para tratamento prevenção, inibição e/ou redução da formação de biofilmes bacterianos
BR112017025995A2 (pt) inibidor de igfbp3, composição farmacêutica para uso no tratamento e/ou prevenção de um distúrbio intestinal, método para o diagnóstico de um distúrbio intestinal em um indivíduo e kit para o diagnóstico de um distúrbio intestinal
WO2019098810A3 (ko) 신규 유산균 및 이의 용도
BR112017023636A2 (pt) suplemento dietético
MX385097B (es) Probiótico o prebiótico, método para la producción del mismo, preparación microbiana, alimento saludable y medicina.
CL2019001938A1 (es) Composiciones probióticas y usos de las mismas.
Ghaziasgar et al. Virulence factors, biofilm formation and antibiotic resistance pattern in Enterococcus faecalis and Enterococcus faecium isolated from clinical and commensal human samples in Isfahan, Iran
MX2022008666A (es) Composicion probiotica para su uso como antioxidante.
Nowak et al. β-Glucuronidase and β-glucosidase activity and human fecal water genotoxicity in the presence of probiotic lactobacilli and the heterocyclic aromatic amine IQ in vitro
IN2012DN06392A (es)
Kamlárová et al. Improvement of the inflammation-damaged intestinal barrier and modulation of the gut microbiota in ulcerative colitis after FMT in the SHIME® model